Medical Developments International Limited

Group revenue was $42.6 million, up 9% year over year. Pain Management revenue increased 21%, with Europe up 12% to $9 million, Australia up 16% to $17.9 million, and Rest of World up strongly to $4.1 million; Respiratory revenue declined 15%. Free cash flow was $4.2 million, $5.8 million higher than FY '25, operating cash flow was $5.8 million, and cash ended at $21.4 million. EBIT and NPAT both improved, though the company did not provide consolidated EBIT or EPS figures in the call. For FY '27, management expects higher end-market demand for Penthrox supported by the European pediatric indication and the recently published Australian health economic study, stable respiratory demand, no repeat of the FY '26 inventory stocking benefit, and approximately $1 million of amortization related to the European pediatric indication registration costs.

Brent MacGregor framed FY '26 as proof that the Penthrox growth strategy is gaining traction, pointing to pediatric label expansion in Europe, UK approval, and new Australian health-economic evidence as key milestones. His tone was constructive and measured: he emphasized that changing prescribing behavior takes time, but said the company is encouraged by the progress and wants to push into new markets and segments in FY '27. He also highlighted disciplined margin management and said the company will keep pursuing operational efficiencies and selective geographic expansion.

Anita James said the financials were pleasing, with 9% revenue growth to $42.6 million despite headwinds in Respiratory. She quantified key segment drivers: Pain Management revenue rose 21%, Europe grew to $9 million, Australia to $17.9 million, and Rest of World to $4.1 million; Segment EBIT for Pain Management improved to $9.4 million. She also noted free cash flow of $4.2 million, operating cash flow of $5.8 million, a $5.2 million working-capital benefit, and year-end cash of $21.4 million, while warning that the working-capital improvement is unlikely to repeat in FY '27. On capital allocation, she said priority one is investing in manufacturing capacity, then growth opportunities, with possible shareholder returns only if surplus capital remains after those needs are assessed.

Analysts focused on whether the new Australian health-economic study could be validated in Europe, hospital-volume growth in Australia, the size and use of the cash balance, and why group EBIT lagged Pain Management EBIT. Management said no European research interest had been confirmed yet, but partners are aware of the study and more real-world evidence generation is expected; they also plan to generate further Australian evidence in FY '27. Brent said Australian hospital Penthrox volumes reached 48,000 units in FY '26, while ambulance remains the foundational and highly penetrated base business with only small single-digit growth expected. On capital management, Anita said investing in manufacturing and growth opportunities comes first, with potential shareholder returns only after those needs are reviewed.